Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

Biodegradable Nanoparticles Maintain Glucose Balance in Mouse Diabetes Model

By BiotechDaily International staff writers
Posted on 30 May 2013
Image: Senior author Dr. Daniel G. Anderson (Photo courtesy of Massachusetts Institute of Technology).
Image: Senior author Dr. Daniel G. Anderson (Photo courtesy of Massachusetts Institute of Technology).
Diabetes researchers have developed an acid-degradable polymeric "nanonetwork" made up of nanoparticles loaded with insulin that can detect elevated glucose levels in the blood of diabetics and then release the hormone to return glucose levels to normal.

Investigators at the Massachusetts Institute of Technology (Cambridge, USA) adapted nanotechnology techniques that they had developed for anticancer drug delivery to address the problem of maintaining the glucose balance in diabetes patients.

They prepared a gel-like structure containing a mixture of oppositely charged nanoparticles that by attracting each other could maintain the integrity of the gel and prevent individual nanoparticles from becoming detached. Each nanoparticle was a dextran sphere containing insulin and an enzyme capable of converting glucose to gluconic acid. The structure of the dextran sphere allowed glucose to diffuse freely, so when sugar levels in the blood were elevated, the enzyme produced large quantities of gluconic acid, lowering the pH of the local environment. The acidic environment caused the dextran spheres to disintegrate, releasing insulin into the bloodstream.

The nanoparticle gel was tested in a Type I diabetes mouse model. Results published in the May 2, 2013, online edition of the journal ACS Nano revealed that a single subcutaneous injection of the gel corrected glucose imbalance and maintained normal blood-sugar levels in the animals for an average of 10 days. As the particles were mostly composed of polysaccharides, they were biocompatible and eventually degraded in the body.

“Insulin really works, but the problem is people do not always get the right amount of it. With this system of extended release, the amount of drug secreted is proportional to the needs of the body,” said senior author Dr. Daniel Anderson, associate professor of chemical engineering at the Massachusetts Institute of Technology.

Related Links:

Massachusetts Institute of Technology



comments powered by Disqus

Channels

Genomics/Proteomics

view channel

New Program Encourages Wide Distribution of Genomic Data

A new data sharing program allows genomics researchers and practitioners to analyze, visualize, and share raw sequence data for individual patients or across populations straight from a local browser. The sequencing revolution is providing the raw data required to identify the genetic variants underlying rare diseases... Read more

Lab Technologies

view channel

Experimental Physicists Find Clues into How Radiotherapy Kills Cancer Cells

A new discovery in experimental physics has implications for a better determination of the process in which radiotherapy destroys cancer cells. Dr. Jason Greenwood from Queen’s University Belfast (Ireland) Center for Plasma Physics collaborated with scientists from Italy and Spain on the work on electrons, and published... Read more

Business

view channel

Interest in Commercial Applications for Proteomics Continues to Grow

Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies. Proteomics is the study of the structure and function of proteins.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.